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Identifying people at risk of cardiovascular diseases (CVD) is a cornerstone of preventative
cardiology. Risk prediction models currently recommended by clinical guidelines are typi-
cally based on a limited number of predictors with sub-optimal performance across all
patient groups. Data-driven techniques based on machine learning (ML) might improve the
performance of risk predictions by agnostically discovering novel risk predictors and learn-
ing the complex interactions between them. We tested (1) whether ML techniques based on
a state-of-the-art automated ML framework (AutoPrognosis) could improve CVD risk predic-
tion compared to traditional approaches, and (2) whether considering non-traditional vari-
ables could increase the accuracy of CVD risk predictions.
Methods and findings
Using data on 423,604 participants without CVD at baseline in UK Biobank, we developed a
ML-based model for predicting CVD risk based on 473 available variables. Our ML-based
model was derived using AutoPrognosis, an algorithmic tool that automatically selects and
tunes ensembles of ML modeling pipelines (comprising data imputation, feature processing,
classification and calibration algorithms). We compared our model with a well-established
risk prediction algorithm based on conventional CVD risk factors (Framingham score), a
Cox proportional hazards (PH) model based on familiar risk factors (i.e, age, gender, smok-
ing status, systolic blood pressure, history of diabetes, reception of treatments for hyperten-
sion and body mass index), and a Cox PH model based on all of the 473 available variables.
Predictive performances were assessed using area under the receiver operating character-
istic curve (AUC-ROC). Overall, our AutoPrognosis model improved risk prediction (AUC-
ROC: 0.774, 95% CI: 0.768-0.780) compared to Framingham score (AUC-ROC: 0.724,
95% CI: 0.720-0.728, p < 0.001), Cox PH model with conventional risk factors (AUC-ROC:
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0.734, 95% CI: 0.729-0.739, p < 0.001), and Cox PH model with all UK Biobank variables
(AUC-ROC: 0.758, 95% CI: 0.753-0.763, p < 0.001). Out of 4,801 CVD cases recorded
within 5 years of baseline, AutoPrognosis was able to correctly predict 368 more cases com-
pared to the Framingham score. Our AutoPrognosis model included predictors that are not
usually considered in existing risk prediction models, such as the individuals’ usual walking
pace and their self-reported overall health rating. Furthermore, our model improved risk pre-
diction in potentially relevant sub-populations, such as in individuals with history of diabetes.
We also highlight the relative benefits accrued from including more information into a predic-
tive model (information gain) as compared to the benefits of using more complex models
(modeling gain).
Conclusions
Our AutoPrognosis model improves the accuracy of CVD risk prediction in the UK Biobank
population. This approach performs well in traditionally poorly served patient subgroups.
Additionally, AutoPrognosis uncovered novel predictors for CVD disease that may now be
tested in prospective studies. We found that the “information gain” achieved by considering
more risk factors in the predictive model was significantly higher than the “modeling gain”
achieved by adopting complex predictive models.
Introduction
Globally, cardiovascular disease (CVD) remains the leading cause of morbidity and mortality
[1]. Current clinical guidelines for primary prevention of CVD emphasize the need to identify
asymptomatic patients who may benefit from preventive action (e.g., initiation of statin ther-
apy [2]) based on their predicted risk [3–6]. Different guidelines recommend different algo-
rithms for risk prediction. For example, the 2010 American College of Cardiology/American
Heart Association (ACC/AHA) guideline [7] recommended use of Framingham Risk Score
[4], whereas the 2016 European guidelines recommended use of the Systematic Coronary Risk
Evaluation (SCORE) algorithm [8]. In the UK, the current National Institute for Health and
Care Excellence (NICE) guidelines recommend use of the QRISK2 score to guide the initiation
of lipid lowering therapies [9, 10].
Existing risk prediction algorithms are typically developed using multivariate regression
models that combine information on a limited number of well-established risk factors, and
generally assume that all such factors are related to the CVD outcomes in a linear fashion, with
limited or no interactions between the different factors. Because of their restrictive modeling
assumptions and limited number of predictors, existing algorithms generally exhibit modest
predictive performance [11], especially for certain sub-populations such as individuals with
diabetes [12–15] or rheumatoid arthritis [3]. Data-driven techniques based on machine
learning (ML) can improve the performance of risk predictions by exploiting large data reposi-
tories to agnostically identify novel risk predictors and more complex interactions between
them. However, only a few studies have investigated the potential advantages of using ML
approaches for CVD risk prediction, focusing only on a limited number of ML methods [16,
17] or a limited number of risk predictors [18].
Here, we aim to assess the potential value of using ML approaches to derive risk prediction
models for CVD. We analyzed data on 423,604 participants without CVD at baseline in UK
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Biobank, a large prospective cohort study in which participants were recruited from 22 centers
throughout the UK. We used a state-of-the-art automated ML method (AutoPrognosis) to
develop ML-based risk prediction models and evaluated their predictive performances in the
overall population and clinically relevant sub-populations. In this paper, we do not focus on
the algorithmic aspects of the ML methods involved and rather focus on their clinical applica-
tion. Methodological details on our automated ML algorithm can be found in our technical
publication in [19].
Materials and methods
Study design and participants
Participants were enrolled in the UK Biobank from 22 assessment centers across England,
Wales, and Scotland, during the period spanning from 2006 to 2010 [20]. We extracted a
cohort of participants who were 40 years of age or older and had no known history of CVD at
baseline. That is, patients with previous history of coronary heart disease, other heart disease,
stroke, transient ischaemic attack, peripheral arterial disease, or cardiovascular surgery were
excluded from the analysis. The total number of participants who met the inclusion criteria
was 423,604. The last available date of participant follow-up was Feb 17, 2016. UK Biobank
obtained approval from the North West Multi-centre Research Ethics Committee (MREC),
and the Community Health Index Advisory Group (CHIAG). All participants provided writ-
ten informed consent prior to enrollment in the study. The UK Biobank protocol is available
online [21].
The UK Biobank dataset keeps track of a large number of variables for each participant, but
most of those variables are missing for most patients. In order to include the maximum possi-
ble number of (informative) variables in our analysis, we included all variables that are missing
for less than 50% of patients with CVD outcomes. This corresponded to a rate of missingness
of 85% for the entire population of participants. Our rationale for assessing the missingness
rate among patients with CVD is that missingness itself maybe informative (i.e., the chance of
a variable being missing may depend on the outcome). By excluding all variables that were
missing for more than 85% of the participants, a total of 473 variables were included in our
analysis. We categorized all variables in the UK Biobank into 9 categories: health and medical
history, lifestyle and environment, blood assays, physical activity, family history, physical mea-
sures, psychosocial factors, dietary and nutritional information, and sociodemographics [22].
The (categorized) lists of variables involved in our analysis are provided in the supporting
information (S1 to S9 Tables).
Outcome
The primary outcome was the first fatal or non-fatal CVD event. A CVD event was defined as
the assignment of any of the ICD-10 diagnosis codes F01 (vascular dementia), I20-I25 (coro-
nary/ischaemic heart diseases), I50 (heart failure events, including acute and chronic systolic
heart failures), and I60-I69 (cerebrovascular diseases), or any of the ICD-9 codes 410-414
(ischemic heart disease), 430-434, and 436-438 (cerebrovascular disease). Follow-up data was
obtained from the hospital episode statistics (a data warehouse containing records of all
patients admitted to NHS hospitals), and the equivalent datasets in Scotland and Wales [23].
Models tested
Framingham Risk Score. At the time of conducting this study, the UK Biobank had not
yet released data on the participants’ total cholesterol, HDL cholesterol and LDL cholesterol,
Cardiovascular disease risk prediction using automated machine learning
PLOS ONE | https://doi.org/10.1371/journal.pone.0213653 May 15, 2019 3 / 17
which are used as predictors in various established algorithms, such as Framingham score [4],
ACC/AHA [24], QRISK2 [9], and SCORE [5]. The Framingham score, however, provides an
incarnation of its underlying model based on nonlaboratory predictors, which replaces lipids
with Body Mass Index (BMI) [4]. Since BMI is currently collected for 99.38% of the UK Bio-
bank participants, we compared our model with the BMI version of the Framingham score.
We used the published predicting equations (beta-coefficients and survival functions) of the
BMI-based Framingham model developed in [4]. (Framingham risk calculator and model
coefficients are publicly available in: https://www.framinghamheartstudy.org.)
The Framingham score is based on 7 core risk factors: gender, age, systolic blood pressure,
treatment for hypertension, smoking status, history of diabetes, and BMI. All of those variables
were complete for the participants in the extracted cohort, with the exception of systolic blood
pressure (missing for 6.8% of the participants), and BMI (missing for 0.62% of the partici-
pants). We used the MissForest non-parametric data imputation algorithm [25] to recover the
missing values. Using the MissForest algorithm, we sampled 5 imputed datasets and averaged
the model predictions for each participant on the 5 datasets (this is known in the literature as
Rubin’s rules [25]). The number of imputed datasets was selected via cross-validation.
Cox proportional hazards model. We evaluated the performance of two Cox Propor-
tional Hazards (PH) models derived from the analysis cohort: a model that only uses the tradi-
tional 7 risk factors used by the Framingham score, and a model that uses all of the 473
variables in the UK Biobank. To fit the Cox PH models, we imputed the missing data using the
MissForest imputation algorithm (with 5 imputations). The Cox PH model that uses the tradi-
tional 7 risk factors used by Framingham score can be thought of as a variant of Framingham
score calibrated to the UK population (the Framingham score was originally derived for a US
population). For the Cox PH model that uses all of the 473 predictors, we applied variable
selection using the LASSO method [26]. (Variable selection was applied since fitting the Cox
model with all variables resulted in an inferior performance due to the numerical collapse of
the Cox model solvers in high dimensions.) To apply variable selection, we fit a LASSO regres-
sion model (a linear model penalized with the L1 norm) to predict the (binary) CVD out-
comes. The fitted model gives a sparse solution whereby many of the estimated coefficients are
zero. We select all the variables with non-zero coefficients in the fitted LASSO model and feed
those variables into a Cox model fitted on the same batch of data. We optimize the LASSO
model regularization parameter via cross-validation.
Standard ML models. We considered 5 standard ML benchmarks that cover different
classes of ML modeling approaches. The models under consideration are: linear support
vector machines (SVM) [27] (a linear classifier), random forest [28] (a tree-based ensemble
method), neural networks [29] (a deep learning method), AdaBoost [30] and gradient boosting
machines [31] (boosting ensemble methods). (We also attempted to fit a kernel SVM, but fit-
ting such a model was computationally infeasible for the UK Biobank cohort because it entails
a cubic complexity in the number of datapoints.) The purpose of including those models in
our experimental evaluations is to ensure that AutoPrognosis has automatically selected and
tuned the best possible ML model, and that no individually-tuned ML model performed better
than the model selected by AutoPrognosis. (We decided to include a Gradient boosting model
in retrospect because it was assigned the largest weight in the ensemble formed by AutoProg-
nosis.) We implemented all these models using the Scikit-learn library in Python program-
ming language [32]. The models’ hyper-parameters were determined via grid search. Data
imputation for all models was conducted using the MissForest algorithm (with 5 imputed
datasets). (We have attempted other imputation algorithms, such as multiple imputation by
chained equations, but MissForest provided a better predictive performance.)
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Model development using AutoPrognosis
We developed an ML-based model for CVD risk prediction using AutoPrognosis, an algorith-
mic framework for automating the design of ML-based clinical prognostic models [19]. A
schematic for the AutoPrognosis framework is provided in Fig 1. Given the participants’ vari-
ables and CVD outcomes, AutoPrognosis uses an advanced Bayesian optimization technique
[33, 34] in order to (automatically) design a prognostic model made out of a weighted ensem-
ble of ML pipelines. Each ML pipeline comprises design choices for data imputation, feature
processing, classification and calibration algorithms (and their hyper-parameters). (Calibra-
tion means that the numerical outputs of a model correspond to the actual risk of a CVD
event. That is, an output prediction of 20% means that the patient’s 5-year risk of a CVD event
is 20%.) The design space of AutoPrognosis contains 5,460 possible ML pipelines (7 possible
imputation algorithms, 9 feature processing algorithms, 20 classification algorithms, and 3 cal-
ibration methods). The list of algorithms that constitute the design space of AutoPrognosis is
provided in Table 1. A detailed technical and methodological description of AutoPrognosis
can be found in our previous work in [19].
To train our model, we set AutoPrognosis to conduct 200 iterations of the Bayesian optimi-
zation procedure in [19], where in each iteration the algorithm explores a new ML pipeline
and tunes its hyper-parameters. Cross-validation was used in every iteration to evaluate the
performance of the pipeline under evaluation. The (in-sample) model learned by AutoProgno-
sis combined 200 weighted ML pipelines, the strongest of which comprised the MissForest
data imputation algorithm, no feature processing steps, an XGBoost ensemble classifier (with
200 estimators) [35], and sigmoid regression for calibration. Details of the model learned by
AutoPrognosis is provided in the supporting information (S1 Appendix). In the Results Sec-
tion, we will directly refer to our model as “AutoPrognosis”.
Variable ranking
In order to identify the relative importance of the 473 variables used to build our model, we
use a post-hoc approach to rank the contribution of the different variables in the predictions
issued by the model. The ranking is obtained by fitting a random forest model with the partici-
pants’ variables as the inputs, and the predictions of our model as the outputs, and then
Fig 1. An illustrative schematic for AutoPrognosis. In this depiction, AutoPrognosis constructs an ensemble of three ML pipelines. Pipeline 1 uses the MissForest
algorithm to impute missing data, and then compresses the data into a lower-dimensional space using the principal component analysis (PCA) algorithm, before using
the random forest algorithm to issue predictions. Pipelines 2 and 3 use different algorithms for imputation, feature processing, classification and calibration.
AutoPrognosis uses the algorithm in [19] to make decisions on what pipelines to select and how to tune the pipelines’ parameters.
https://doi.org/10.1371/journal.pone.0213653.g001
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assigning variable importance scores to the different variables using the standard permutation
method in [36]. Using the permutation method, we assess the mean decrease in classification
accuracy for every variable after permuting that variable over all trees. The resulting variable
importance scores reflect the impact each variable has on the predictions issued by AutoProg-
nosis. We used the random forest algorithm for post-hoc variable ranking because it is a non-
parametric algorithm that can recognize complex patterns of variable interaction while
enabling principled evaluation of variable importance [36]. Other variable ranking methods
based on associative classifiers (such as the one proposed in [19]) entail a computational com-
plexity that is exponential in the number of variables, and hence are not suitable for our study
as it involves more than 400 variables.
To disentangle the “modeling gain” achieved by utilizing ML-based techniques from the
“information gain” achieved by just using more variables, we created a simpler version of
AutoPrognosis that only uses the same 7 core risk factors (age, gender, systolic blood pressure,
smoking status, treatment of hypertension, history of diabetes, and BMI) used by the existing
prediction algorithms. In addition, we created another version of the AutoPrognosis model
that uses only non-laboratory variables in UK Biobank.
Statistical analysis
In order to avoid over-fitting, we evaluated the prediction accuracy of all models under consid-
eration via 10-fold stratified cross-validation using area under the receiver operating charac-
teristic curve (AUC-ROC). In every cross-validation fold, a training sample (381,244
participants) was used to derive the Cox PH models, standard ML models, and our model
(AutoPrognosis), and then a held-out sample (42,360 participants) was used for performance
evaluation. We report the mean AUC-ROC and the 95% confidence intervals (Wilson score
intervals) for all models. The calibration performance of our model was evaluated via the Brier
score.
Table 1. List of algorithms included in AutoPrognosis.
Pipeline Stage Algorithms








Feature Process • Feature agglomeration




























Calibration • Calibration • Sigmoid • none
MICE: multiple imputation by chained equations, EM: expectation maximization, PCA: principal component analysis, ICA: independent component analysis, SVM:
support vector machines, NB: Naïve Bayes, NN: nearest neighbors, LDA: linear discriminant analysis, GBM: gradient boosting machine.
https://doi.org/10.1371/journal.pone.0213653.t001
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Results
Characteristics of the study population
A total of 423,604 participants had sufficient information for inclusion in this analysis. Overall,
the mean (SD) age of participants at baseline was 56.4 (8.1) years, and 188,577 participants
(44.5%) were male. Over a median follow-up of 7 years (5th-95th percentile: 5.7-8.4 years; 3
million person-years at risk), there were 6,703 CVD cases. The mean age of CVD cases was
60.5 years (60.2 years for men and 61.1 years for women). Because the minimum follow-up
period for all participants was 5 years, we evaluated the accuracy of the different models in pre-
dicting the 5-year risk of CVD. At a 5-year horizon, the total number of CVD cases was 4,801.
Prediction accuracy
Comparison of prediction models. The prediction accuracy of the different models
under consideration evaluated at a 5-year horizon is shown in Table 2. We used the Framing-
ham score as a baseline model for performance evaluation (AUC-ROC: 0.724, 95% CI: 0.720-
0.728). Both the Cox PH model with the 7 conventional risk factors (AUC-ROC: 0.734, 95%
CI: 0.729-0.739), and the Cox PH model with all variables (AUC-ROC: 0.758, 95% CI: 0.753-
0.763) achieved an improvement in the AUC-ROC compared to the baseline model (p<
0.001). The improvement achieved by the Cox PH model that uses the same predictors used by
the Framingham score is due in part to the fact that the Cox PH model is directly derived from
the analysis cohort, whereas the Framingham score coefficients were derived from a different
population.
With the exception of support vector machines, all the standard ML models achieved statis-
tically significant improvements compared to the baseline Framingham score. Furthermore,
when compared to the Cox PH model that uses all variables, neural networks, AdaBoost, gradi-
ent boosting, and AutoPrognosis all achieved a significantly higher AUC-ROC. AutoPrognosis
achieved a higher AUC-ROC compared to all other standard ML models (AUC-ROC: 0.774,
95% CI: 0.768-0.780, p< 0.001), which suggests that the automated ML system managed to
automatically select and tune the “right” ML model. (The AutoPrognosis model trained on all
variables was also well-calibrated, with an in-sample Brier score of 0.0121.) Compared to the
most competitive benchmark (the Cox PH model that uses all of the variables), the net re-
Table 2. Performance of all prediction models under consideration.
Model AUC-ROC Absolute AUC-ROC Change
Framingham Score 0.724 ± 0.004 Baseline model
Cox PH Model (7 core variables) 0.734 ± 0.005 + 1.0%
Cox PH Model (all variables) 0.758 ± 0.005 + 3.4%
Support Vector Machines 0.709 ± 0.061 - 1.5%
Random Forest 0.730 ± 0.004 + 0.6%
Neural Networks 0.755 ± 0.005 + 3.1%
AdaBoost 0.759 ± 0.004 + 3.5%
Gradient Boosting 0.769 ± 0.005 + 4.5%
AutoPrognosis (7 core variables) 0.744 ± 0.005 + 2.0%
AutoPrognosis (369 non-lab. variables) 0.761 ± 0.005 + 3.7%
AutoPrognosis (104 lab. variables) 0.735 ± 0.008 + 1.1%
AutoPrognosis (all variables) 0.774 ± 0.005 + 5.0%
The Framingham score is provided as the reference model for comparative purposes.
https://doi.org/10.1371/journal.pone.0213653.t002
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classification index (NRI) was +12.5% in favor of AutoPrognosis. AutoPrognosis trained only
with the 7 conventional risk factors still outperformed the baseline Framingham score (p<
0.001).
Most of the variables in the UK Biobank are non-laboratory variables collected through an
automated touchscreen questionnaire about lifestyle, clinical history and nutritional habits.
We evaluated the accuracy of AutoPrognosis once when it is trained with 369 variables corre-
sponding to the participants’ self-reported information (questionnaires) only, and once when
it is trained with 104 variables obtained from blood assays, diagnostic tests, and physiological
measurements. As we can see in Table 2, AutoPrognosis with only questionnaire-related
variables still achieves a significant improvement over the baseline Framingham score
(AUC-ROC: 0.752, 95% CI: 0.747-0.757, p< 0.001), and is superior to the model that only
uses laboratory-based variables.
Classification analysis. In order to better assess the clinical significance of our results, we
compared the AutoPrognosis model with the traditional Framingham score in predicting 7.5%
CVD risk (threshold for initiating lipid-lowering therapies recommended by the NICE guide-
lines [10]). At this operating point, the Framingham baseline model predicted 2,989 CVD
cases correctly from 4,801 total cases, resulting in a sensitivity of 62.2% and PPV of 1.5%. Our
AutoPrognosis model correctly predicted 3,357 out of the 4,801 CVD cases, resulting in a sen-
sitivity of 69.9% and PPV of 2.6%. This corresponds to 368 net increase in the number of CVD
patients who would benefit from receiving a preventive treatment in a timely manner when
utilizing the predictions of our model.
Variable importance. Table 3 lists the 20 most important variables ranked according to
their contribution to the predictions of the AutoPrognosis model (along with their importance
Table 3. Variable ranking by their contribution to the predictions of AutoPrognosis.
Variable (Men) Score Variable (Women) Score
Age� 0.346 Age� 0.370
Smoking� 0.101 Smoking� 0.099
Usual walking pace 0.052 Usual walking pace 0.057
Systolic blood pressure� 0.040 Ankle spacing width 0.035
Microalbumin in urine 0.032 Self-reported health rating 0.030
High blood pressure 0.030 Systolic blood pressure� 0.026
Red blood cell distribution width 0.025 High blood pressure 0.024
Self-reported health rating 0.019 Red blood cell distribution width 0.023
Haematocrit percentage 0.014 Microalbumin in urine 0.017
Father age at death 0.014 Father age at death 0.017
BMI� 0.013 White blood cell count 0.011
Diastolic blood pressure 0.012 Number of Treatments 0.011
White blood cell count 0.012 Mean reticulocyte volume 0.008
Impedance of arm (left) 0.009 Leg predicted mass (right) 0.006
Haemoglobin concentration 0.007 Neutrophill count 0.006
Neutrophill count 0.005 Basal metabolic rate 0.005
Number of Treatments 0.004 Hormone-replac. therapy usage 0.005
Mean reticulocyte volume 0.004 Blood clot in the leg 0.004
Urinary sodium concentration 0.004 Forced expiratory volume 0.004
Monocyte count 0.004 Duration of fitness test 0.004
� Risk factors utilized by existing risk prediction algorithms.
Explanations for the different variables in this table are provided in S2 Appendix.
https://doi.org/10.1371/journal.pone.0213653.t003
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scores). Variables related to physical activity (usual walking pace) and information on blood
measurements appeared to be more important for the predictions of AutoPrognosis than tra-
ditional risk factors included in most existing scoring systems. For women, a remarkable pre-
dictor of CVD risk was the measured “ankle spacing width”. This may be linked to symptoms
of poor circulation, such as swollen legs, which is predictive of future CVD events [37]. We
also found that usage of hormone-replacement therapy (HRT) was on the list of top predictors
of CVD risk for women. For men, blood measurements such as haematocrit percentage and
haemoglobin concentration, and variables such as urinary sodium concentration were among
the most important risk factors.
Prediction accuracy in individuals with history of diabetes. Among the 423,604 partici-
pants included in our cohort, a total of 17,908 participants (4.22%) had a known history of dia-
betes (either Type 1 or Type 2) at baseline. In Table 4, we show the AUC-ROC performance of
AutoPrognosis and the baseline Framingham score when validated separately on the diabetic
and non-diabetic populations. As we can see, the baseline Framingham score was less accurate
in the diabetic population (AUC-ROC: 0.578, 95% CI: 0.560-0.596) compared to its achieved
accuracy for the overall population (AUC-ROC: 0.724, 95% CI: 0.720-0.728, p< 0.001). On
the contrary, AutoPrognosis maintained high predictive accuracy for the diabetic population
(AUC-ROC: 0.713, 95% CI: 0.703-0.723).
The variable ranking for the diabetic sub-population is provided in Table 5. We note that
the list of important variables in the diabetic subgroup is substantially different from that of
the overall population. One major difference is that for diabetic patients, microalbuminuria
appeared to be strongly linked to an elevated CVD risk. In the overall population (423,604
Table 4. Performance of AutoPrognosis in the diabetic patient subgroup.
Model AUC-ROC (No diabetes) AUC-ROC (Diabetes)
Framingham score 0.724 ± 0.004 0.578 ± 0.018
AutoPrognosis 0.774 ± 0.005 0.713 ± 0.010
Performance of AutoPrognosis and the Framingham score validated separately on a testing cohort of diabetic
patients (1,790 participants), and a testing cohort of non-diabetic patients (40,570 participants) via 10-fold cross-
validation. AutoPrognosis was trained using the entire training cohort that combines both diabetic and non-diabetic
individuals (381,244 participants).
https://doi.org/10.1371/journal.pone.0213653.t004
Table 5. Variable ranking for the diabetic population.
Variable Score
Age 0.207
Microalbumin in urine 0.110
Usual walking pace 0.078
Smoking status 0.064
Systolic blood pressure 0.034
Red blood cell distribution width 0.027
Neutrophill count 0.018
Number of Treatments 0.018
High blood pressure 0.014
Urinary sodium concentration 0.014
https://doi.org/10.1371/journal.pone.0213653.t005
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participants), the average measure of microalbumin in urine was 27.8 mg/L for participants
with no CVD events, and 52.2 mg/L for participants with CVD events. In the diabetic popula-
tion (17,908 participants), participants with no CVD events had an average microalbumin in
urine of 61.0 mg/L, whereas for those with a CVD event, the average microalbumin in urine
was 128.76 mg/L. (Information on microalbumin in urine was available for 30% of the patients
in the overall population, and 50% of patients in the diabetic population.)
Predictive ability of individual variables in UK Biobank. In order to evaluate the indi-
vidual predictive ability of the UK Biobank variables, we exhaustively fitted simple versions of
our AutoPrognosis model for each of the 473 variables. For each such model, we use one dis-
tinct variable as an input and evaluate the resulting AUC-ROC. Because most variables are cor-
related with age and gender, we use the age variable as a second predictor for all models, and
fit separate models for men and women. The AUC-ROC values of the resulting models are
depicted in the scatter-plot in Fig 2.
As shown in Fig 2, variables related to smoking habits or exposure to tobacco smoke dis-
played the highest predictive ability. Self-reported health rating was predictive for both
Fig 2. Predictive ability of the UK Biobank variables for men and women. Each point represents a variable in the
UK Biobank ordered by the ability to predict CVD events for men and women. Predictions based solely on age
achieved an AUC-ROC of 0.632 ± 0.003 for men and 0.665 ± 0.002 for women. We report the AUC-ROC from models
trained with individual variables in addition to age, and only display variables that achieved a statistically significant
improvement in AUC-ROC compared to predictions based on age only. Each color represents a different variable
category. Variables deviating from the (dotted gray) regression line have an AUC-ROC that differs between men and
women more than expected in view of the overall association between the two genders, suggesting a stronger relative
importance in one gender group.
https://doi.org/10.1371/journal.pone.0213653.g002
Cardiovascular disease risk prediction using automated machine learning
PLOS ONE | https://doi.org/10.1371/journal.pone.0213653 May 15, 2019 10 / 17
genders, but more predictive for women. Existence of long-standing illness was strongly pre-
dictive of CVD events for women, and less predictive for men. Variables extracted from the
electrocardiogram (ECG) records possessed stronger predictive ability for men.
Discussion
In this large prospective cohort study, we developed a ML model based on the AutoPrognosis
framework for predicting CVD events in asymptomatic individuals. The model was built
using data for more than 400,000 UK Biobank participants, with over 450 variables for each
participant. Our study conveys several key messages. First, AutoPrognosis significantly
improved the accuracy of CVD risk prediction compared to well-established scoring systems
based on conventional risk factors and currently recommended by primary prevention guide-
lines (Framingham score). Second, AutoPrognosis was able to agnostically discover new pre-
dictors of CVD risk. Among the discovered predictors were non-laboratory variables that can
be collected relatively easily via questionnaires, such as the individuals’ self-reported health rat-
ings and usual walking pace. Third, AutoPrognosis uncovered complex interaction effects
between different characteristics of an individual, which led to recognition of risk predictors
that are specific to certain sub-populations for whom existing guidelines were providing unre-
liable predictions.
When can ML help in prognostic modeling?
The abundance of a large number of informative variables in the UK Biobank (473 variables)
guarantees an “information gain” that can be achieved by any data-driven model, including
the standard Cox PH model, compared to the existing prediction algorithms that use only a
limited number of conventional risk factors (e.g., Framingham score). The results in Table 2
show that, in addition to the information gain, AutoPrognosis also attained a “modeling gain”
that allowed it to outperform the standard Cox PH model that uses all of the 473 variables. In
general, the modeling gain achieved by AutoPrognosis would result from its ability to select
among different models with various levels of complexity and numerical robustness in a
completely data-driven fashion, without committing to any presupposition about the superior-
ity of any given model. In our experiments, the Cox PH supplied with all of the 473 variables
(without variable selection) provided a noticeably poor performance (i.e., an average
AUC-ROC of 0.6). This is because the numerical solvers of the Cox PH model collapse when
the data dimensionality is very large—this is why a variable selection pre-processing step was
essential for fitting the Cox PH model. This implies that, even if the true underlying data
model is perfectly linear, fitting standard linear models such as Cox PH or linear regression
may not be sufficient for harnessing the information gain, since such models are not numerical
robust in high-dimensional settings. AutoPrognosis solves this problem by selecting more
robust models that better fit the high-dimensional data—in our experiments, these where tree-
based models such as XGBoost and random forests. This observation shows that information
gain and modeling gain are inherently entangled: to harness the information gain, we need to
consider a more complex modeling space.
While the information gain appeared to be more significant than the modeling gain in our
experiments, we note that even when provided with the same 7 core risk factors used by the
Framingham score, AutoPrognosis was still able to offer a statistically significant AUC-ROC
gain compared to the Framingham score and a Cox PH model that uses the same 7 variables.
This shows that the modeling gain is not necessarily limited to settings where many predictors
are available and numerical robustness, but is rather achievable whenever a small number of
predictors display complex interactions.
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Because not every ML model would necessarily improve over the Framingham score or the
simple Cox PH model, our usage of the AutoPrognosis algorithm was essential for realizing
the full benefits of ML modeling. As the results in Table 2 demonstrate, some ML models did
not improve over the baseline Framingham score, whereas others provided modest improve-
ments. This is because selection of the right ML model and careful tuning for the model’s
hyper-parameters are two crucial steps for realizing the potential benefits of ML. AutoProgno-
sis automates those steps, which makes ML application easily accessible for mainstream clini-
cal research. The importance of model selection and hyper-parameter optimization have been
overlooked in previous clinical studies that applied ML in prognostic modeling [16–18]. Our
study is unique in that, to the best of our knowledge, it is the first to carry out a comprehensive
investigation of the performance of ML models in a large cohort with such an extensive num-
ber of predictors.
Risk prediction with non-laboratory variables
Individuals in developed countries tend to seek out health information through online
resources and web-based risk calculators [38]. In developing countries, where 80% of all
world-wide CVD deaths occur [39], there are limited resources for risk assessment strategies
that require laboratory testing [39, 40]. The results in Table 2 show that AutoPrognosis could
potentially provide reliable risk predictions by using information from non-laboratory vari-
ables about the participants’ lifestyle and medical history. The most predictive non-laboratory
variables included in our model were ages, gender, smoking status, usual walking pace, self-
reported overall health rating, previous diagnoses of high blood pressure, income, Townsend
index and parents’ ages at death. Inclusion of such variables in web-based risk calculators can
help provide reasonably accurate risk predictions when obtaining laboratory variables is not
viable.
One remarkable finding in Table 2 (and Fig 2) is that apart from the well-established age
and gender risk factors, two other non-laboratory variables were found to be very predictive of
the CVD outcomes; those are the “self-reported health rating”, and the “usual walking pace”.
(Both variables were also found to be predictive of the overall mortality risk in a recent study
on the UK Biobank [22].) Neither of the two variables is included in any of the existing risk
prediction tools. Walking pace was equally predictive for men and women, but the self-
reported health rating was more predictive for women and less for men. This may be explained
by either gender-specific reporting bias or true clinical differences. Therefore, prediction tools
that would include subjective non-laboratory variables, such as the self-reported health rating,
should be carefully designed in such a way that self-reporting bias is reduced.
Risk predictors specific to diabetic patients
Unlike the Framingham score, AutoPrognosis was able to maintain high predictive accuracy
for participants diagnosed with diabetes at baseline (Table 4). This suggests that the AutoProg-
nosis model has learned diabetes-specific risk factors that were not previously captured by the
existing prediction algorithms. By investigating the risk factor ranking within the diabetic sub-
group (Table 5), we found that urinary microalbumin (measured in mg/L) is a very strong
marker for increased CVD risk among individuals with diabetes. The dismissal of urinary
microalbumin in existing risk scoring systems may explain their poor prognostic performance
when validated in cohorts of diabetic patients [12, 13]. Our results indicate that predictions
based on AutoPrognosis can provide better guidance for CVD preventive care in diabetic
patients.
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It is worth mentioning that the microalbumin in urine measures were available for only
125,406 participants in the overall cohort (29.6%). In a standard prognostic study, such a vari-
able may get omitted from the analysis because of its high missingness rate. AutoPrognosis
automatically recognized that this variable is relevant for diabetic patients, and hence did not
omit it in its feature processing stage.
Limitations
The main limitation of our study is the absence of the cholesterol biomarkers (total cholesterol,
HDL cholesterol and LDL cholesterol) from the latest release of the UK Biobank data reposi-
tory, which hindered direct comparisons with the QRISK2 scores currently recommended by
the NICE guidelines. Furthermore, other blood-based biomarkers have been reported to be
associated with CVD risk, but were also not yet released in the UK Biobank data repository,
such as triglycerides [41], measures of glycemia [42], markers of inflammation [43], and and
natriuretic peptides [44]. Inclusion of such predictors could improve the predictive accuracy
of all models tested in this study, and could also alter the risk predictors’ ranking in Table 2,
but is unlikely to change our conclusions on the usefulness of ML modeling in CVD risk
prediction.
Another limitation of our study is that the UK Biobank cohort is ethnically homogeneous:
94% of the participants were of white ethnicity. Hence, assessment of the importance of ethnic-
ity as a predictor of CVD events and the recognition of ethnicity-specific risk predictors was
not possible in our study.
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